Loading…
In the quest to discover the most effective cancer therapy, it is important to take into account not only the somatic mutations present in cancer cells but also the germline gene variations that play a role in regulating immune responses .
A comprehensive evaluation was conducted on 187 studies concerning cancer treatment, which resulted in 176 approvals for 75 distinct novel cancer drugs by the FDA. Among these studies, 64 (34%) were single-arm clinical trials, while 123 (63%) were randomized clinical trials. Within the 123 randomized clinical trials, 37 (30%) demonstrated no survival benefit, 31 (25%) exhibited suboptimal control, and 17 (14%) involved inappropriate crossover. It was found that two-thirds of cancer drugs receive approval based on clinical trials that have limitations in at least one of four critical areas.
Most efficient tumor uptake can be obtained with large antibodies such as IgG, exceeding the size limit for renal clearance and with very small proteins with high binding affinity (long Off-rate).
The functional state of the host Immune system has a major prognostic and predictive impact on the fate of cancer patients treated with conventional or targeted chemotherapies.
see also:
Cancer / Tumors & Mutations